LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 868 | 662 | 3410 | 0.1945 | -0.1284 |
MDA-MB-231 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 868 | 621 | 3556 | 0.1750 | -0.1523 |
MDA-MB-231 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 868 | 631 | 3410 | 0.1851 | -0.1497 |
MDA-MB-231 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 868 | 527 | 3556 | 0.1482 | -0.2187 |
MDA-MB-231 | CGP60474 | 10 | uM | LJP5 | 72 | hr | 868 | 586 | 3410 | 0.1720 | -0.1804 |
MDA-MB-231 | CGP60474 | 10 | uM | LJP6 | 72 | hr | 868 | 469 | 3556 | 0.1316 | -0.2652 |
MDA-MB-231 | PD173074 | 0.04 | uM | LJP6 | 72 | hr | 868 | 4084 | 3556 | 1.1488 | 1.1413 |
MDA-MB-231 | PD173074 | 0.12 | uM | LJP6 | 72 | hr | 868 | 3919 | 3556 | 1.1027 | 1.0988 |
MDA-MB-231 | PD173074 | 0.37 | uM | LJP6 | 72 | hr | 868 | 3593 | 3556 | 1.0112 | 1.0113 |
MDA-MB-231 | PD173074 | 1.11 | uM | LJP6 | 72 | hr | 868 | 3645 | 3556 | 1.0232 | 1.0205 |
MDA-MB-231 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 868 | 3652 | 3556 | 1.0272 | 1.0266 |
MDA-MB-231 | PD173074 | 10 | uM | LJP6 | 72 | hr | 868 | 1273 | 3556 | 0.3578 | 0.2062 |
MDA-MB-231 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 2483 | 3410 | 0.7277 | 0.7015 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 72 | hr | 868 | 2779 | 3410 | 0.8150 | 0.8031 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 2400 | 3410 | 0.7039 | 0.6738 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1788 | 3410 | 0.5248 | 0.4426 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1133 | 3410 | 0.3325 | 0.1445 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 72 | hr | 868 | 1086 | 3410 | 0.3188 | 0.1205 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3554 | 3556 | 1.0011 | 1.0013 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 72 | hr | 868 | 3667 | 3556 | 1.0338 | 1.0320 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 72 | hr | 868 | 3262 | 3556 | 0.9188 | 0.9185 |
MDA-MB-231 | BMS345541 | 1.11 | uM | LJP6 | 72 | hr | 868 | 2372 | 3556 | 0.6673 | 0.6392 |
MDA-MB-231 | BMS345541 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1189 | 3556 | 0.3351 | 0.1679 |
MDA-MB-231 | BMS345541 | 10 | uM | LJP6 | 72 | hr | 868 | 758 | 3556 | 0.2131 | -0.0650 |
MDA-MB-231 | KIN001-043 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3394 | 3556 | 0.9563 | 0.9563 |